Galmed pharmaceuticals ltd. files annual report on form 20-f for the fiscal year ended december 31, 2024

Tel aviv, israel , april 2, 2025 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ('galmed' or the 'company'), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and gi oncological indications, today announced that it has filed its annual report on form 20-f for the fiscal year ended december 31, 2024, with the u.s. securities and exchange commission (the 'sec').
GLMD Ratings Summary
GLMD Quant Ranking